Company news

Pasithea Therapeutics Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 27, 2024

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

April 28, 2024

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

April 23, 2024

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

February 12, 2024

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

January 7, 2024

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

January 1, 2024

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

December 27, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

December 18, 2023

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

December 10, 2023

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

November 28, 2023

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

November 28, 2023

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

November 8, 2023

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

September 13, 2023

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved su...

July 31, 2023

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

July 19, 2023

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

July 19, 2023

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

June 29, 2023

Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

June 28, 2023

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

June 5, 2023

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

May 31, 2023

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

May 2, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

March 1, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

February 22, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

February 15, 2023

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

January 17, 2023

Majority of Stockholders Support Pasithea Directors at Special Meeting

December 13, 2022

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

December 11, 2022

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

December 5, 2022

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9: 00 AM Eastern Time

November 27, 2022

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

October 16, 2022

Pasithea Therapeutics Acquires AlloMek Therapeutics

October 11, 2022

Pasithea Therapeutics to Call Special Meeting of Stockholders

October 2, 2022

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

September 19, 2022

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

September 14, 2022

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 8, 2022

Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference

August 17, 2022

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

August 10, 2022

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign

August 1, 2022

Pasithea Therapeutics Awarded a Drug Development Research Grant

July 13, 2022

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

June 22, 2022

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

June 21, 2022

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

April 13, 2022

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

March 29, 2022

Pasithea Therapeutics Announces Collaboration with The Glimpse Group

March 7, 2022

Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022

February 23, 2022

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

February 8, 2022

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

February 2, 2022

Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments

January 25, 2022

Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

December 20, 2021

← Newer news releases · Older news releases →

Decks